Is cholecystokinin therapeutic in chronic schizophrenia?

R. A. Boza, D. J. Rotondo

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Cholecystokinin (CCK) has been implicated as a neurotransmitter, and recent research has identified CCK as having potential antipsychotic effects in patients with chronic schizophrenia. Nine chronic schizophrenic patients with prominent psychotic symptoms and a history of resistance to conventional neuroleptic treatment were administered ceruletide, a synthetic decapeptide of cerulein, intramuscularly. No clinically significant short-term or long-term therapeutic effects were demonstrated, despite the results of statistical analysis which indicated significant improvement. The implications of this open clinical trial for a new treatment modality of chronic schizophrenia are discussed.

Original languageEnglish (US)
Pages (from-to)485-486
Number of pages2
JournalJournal of Clinical Psychiatry
Issue number11
StatePublished - Dec 1 1985

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Is cholecystokinin therapeutic in chronic schizophrenia?'. Together they form a unique fingerprint.

Cite this